Compare BioNTech SE - ADR (BNTX) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Southwest Airlines Co — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Southwest Airlines Co trades at $47.75 (market cap $23.25B). The key difference: BioNTech SE - ADR and Southwest Airlines Co are close in size by market cap, and Southwest Airlines Co pays a 1.51% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | LUV | |
|---|---|---|
Market Cap | $22.86B | $23.25B |
Sector | Health | Industrials |
52-Week High | $119.34 | $54.80 |
52-Week Low | $83.89 | $29.06 |
Enterprise Value | $6.53B | $26.31B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Southwest Airlines (LUV) trades at $47.92, down 1.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $52.47 suggesting upside. Recent earnings show a mix of beats and a miss, with Q2 2026 results expected soon. The company maintains a solid balance sheet with a debt-to-asset ratio improving to 16.86% in 2025, though net cash flow remains negative due to significant financing activities.
The outlook is cautiously optimistic, driven by potential earnings growth and cost management, but risks include fuel price volatility and competitive pressures. Analyst sentiment is mixed, with 42% buy ratings, highlighting both recovery potential and near-term headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
